关注
Jae Seung Lee
Jae Seung Lee
Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea
在 yuhs.ac 的电子邮件经过验证
标题
引用次数
引用次数
年份
Hepatitis B virus cure: targets and future therapies
HW Lee, JS Lee, SH Ahn
International journal of molecular sciences 22 (1), 213, 2020
1022020
Cardiovascular risk is elevated in lean subjects with nonalcoholic fatty liver disease
Y Kim, E Han, JS Lee, HW Lee, BK Kim, MK Kim, HS Kim, JY Park, ...
Gut and liver 16 (2), 290, 2022
592022
Risk stratification using sarcopenia status among subjects with metabolic dysfunction‐associated fatty liver disease
HS Chun, MN Kim, JS Lee, HW Lee, BK Kim, JY Park, DY Kim, SH Ahn, ...
Journal of cachexia, sarcopenia and muscle 12 (5), 1168-1178, 2021
392021
A survey on transarterial chemoembolization refractoriness and a real-world treatment pattern for hepatocellular carcinoma in Korea
JS Lee, BK Kim, SU Kim, JY Park, SH Ahn, JS Seong, KH Han
Clinical and Molecular Hepatology 26 (1), 24, 2020
382020
Negligible risks of hepatocellular carcinoma during biomarker-defined immune-tolerant phase for patients with chronic hepatitis B
MY Jeon, BK Kim, JS Lee, HW Lee, JY Park, SH Ahn, KH Han, SU Kim
Clinical and Molecular Hepatology 27 (2), 295, 2021
342021
The modified Response Evaluation Criteria in Solid Tumors (RECIST) yield a more accurate prognoses than the RECIST 1.1 in hepatocellular carcinoma treated with transarterial …
JS Lee, HJ Choi, BK Kim, JY Park, SH Ahn, KH Han, SE Baek, YE Chung, ...
Gut and liver 14 (6), 765, 2020
272020
Empirical treatment with carbapenem vs third-generation cephalosporin for treatment of spontaneous bacterial peritonitis
SW Kim, JS Yoon, J Park, YJ Jung, JS Lee, J Song, HA Lee, YS Seo, ...
Clinical Gastroenterology and Hepatology 19 (5), 976-986. e5, 2021
242021
Effect of tenofovir alafenamide vs. tenofovir disoproxil fumarate on hepatocellular carcinoma risk in chronic hepatitis B
HW Lee, YY Cho, H Lee, JS Lee, SU Kim, JY Park, DY Kim, SH Ahn, ...
Journal of Viral Hepatitis 28 (11), 1570-1578, 2021
212021
Impact of tenofovir alafenamide vs. entecavir on hepatocellular carcinoma risk in patients with chronic hepatitis B
HW Lee, YY Cho, H Lee, JS Lee, SU Kim, JY Park, DY Kim, SH Ahn, ...
Hepatology International 15 (5), 1083-1092, 2021
212021
Association between the severity of liver fibrosis and cardiovascular outcomes in patients with type 2 diabetes
HS Chun, JS Lee, HW Lee, BK Kim, JY Park, DY Kim, SH Ahn, YH Lee, ...
Journal of Gastroenterology and Hepatology 36 (6), 1703-1713, 2021
192021
Fibrotic burden determines cardiovascular risk among subjects with metabolic dysfunction-associated fatty liver disease
E Han, Y Lee, JS Lee, HW Lee, BK Kim, JY Park, SH Ahn, BW Lee, ...
Gut and liver 16 (5), 786, 2022
172022
Liver stiffness-based risk prediction model for hepatocellular carcinoma in patients with nonalcoholic fatty liver disease
JS Lee, DH Sinn, SY Park, HJ Shin, HW Lee, BK Kim, JY Park, DY Kim, ...
Cancers 13 (18), 4567, 2021
152021
Evolution of liver fibrosis and steatosis markers in patients with type 2 diabetes after metformin treatment for 2 years
HW Lee, JS Lee, BK Kim, JY Park, SH Ahn, SU Kim
Journal of Diabetes and its Complications 35 (1), 107747, 2021
152021
An observational study on long‐term renal outcome in patients with chronic hepatitis B treated with tenofovir disoproxil fumarate
TS Lim, JS Lee, BK Kim, HW Lee, MY Jeon, SU Kim, JY Park, DY Kim, ...
Journal of Viral Hepatitis 27 (3), 316-322, 2020
152020
Metabolic dysfunction associated fatty liver disease identifies subjects with cardiovascular risk better than non‐alcoholic fatty liver disease
HS Chun, M Lee, JS Lee, HW Lee, BK Kim, JY Park, DY Kim, SH Ahn, ...
Liver International 43 (3), 608-625, 2023
132023
Predictive performance of CAGE-B and SAGE-B models in Asian treatment-naive patients who started entecavir for chronic hepatitis B
HY Chon, JS Lee, HW Lee, HS Chun, BK Kim, WY Tak, JY Park, ...
Clinical Gastroenterology and Hepatology 20 (4), e794-e807, 2022
132022
Comparison of FibroScan-aspartate aminotransferase (FAST) score and other non-invasive surrogates in predicting high-risk non-alcoholic steatohepatitis criteria
JS Lee, HW Lee, BK Kim, JY Park, DY Kim, SH Ahn, JY Jang, SY Park, ...
Frontiers in Medicine 9, 869190, 2022
122022
Episodic detectable viremia does not affect prognosis in untreated compensated cirrhosis with serum hepatitis B virus DNA< 2,000 IU/mL
HW Lee, SY Park, YR Lee, H Lee, JS Lee, SU Kim, JY Park, SH Ahn, ...
Official journal of the American College of Gastroenterology| ACG 117 (2 …, 2022
122022
Validation of risk prediction scores for hepatocellular carcinoma in patients with chronic hepatitis B treated with entecavir or tenofovir
JW Chang, JS Lee, HW Lee, BK Kim, JY Park, DY Kim, SH Ahn, YS Seo, ...
Journal of Viral Hepatitis 28 (1), 95-104, 2021
122021
Hepatocellular carcinoma risk according to regimens for eradication of hepatitis C virus; interferon or direct acting antivirals
HW Lee, DH Han, HJ Shin, JS Lee, SU Kim, JY Park, DY Kim, SH Ahn, ...
Cancers 12 (11), 3414, 2020
122020
系统目前无法执行此操作,请稍后再试。
文章 1–20